

In-Med develops NeuroShield CT, AI tool to help reduce mortality rates in neurotrauma

09 February 2024 | News

Product is integrated seamlessly into the clinical and radiology workflow and efficiently prioritises critical cases that require immediate attention

In-Med AI has announced the launch of its new product, 'Neuroshield CT TBI', an artificial intelligence (AI) based neurotrauma screening and quantification tool. Grounded in robust research and built on extensive imaging data, NeuroShield CT will aid neuro-critical teams in identifying and quantifying pathologies related to Traumatic Brain Injury (TBI) cases.

Leveraging AI, NeuroShield CT automates manual image processing, ensuring accurate results on a timely basis. This state-of-the-art technology empowers radiologists, neurologists, and neurosurgeons with accurate data, facilitating rapid, informed decision-making around workflow prioritisation, acute triage management, and developing effective treatment plans in the case of neurotrauma. TBI is the primary cause of hospitalisation, disability, and post-injury mortality worldwide, often referred to as a "silent epidemic".

Globally between 64 and 74 million people experience traumatic brain injuries (TBI) every year. According to the Indian Head Injury Foundation (IHIF), India leads the world in brain injury rates, with one in six TBI patients succumbing to their injuries. Early diagnosis is crucial, as 50% of associated mortalities occur within the first 24 hours.

Serving as a decision support tool, Neuroshield CT promptly alerts neurologists to the presence of critical pathologies, offering quantifiable insights. NeuroShield CT provides crucial information, arming neurologists with the knowledge necessary for targeted interventions and improved patient outcomes. This tool is particularly essential for early intervention, a necessity during the "Golden Hour," a critical post-trauma period. The software automatically detects and quantifies bleed (Intracranial Haemorrhage), Fracture, and Midline Shift, and Fracture.

This new product follows the pathbreaking Neuroshield MRI Volumetry product targeting neurodegenerative conditions like dementia, Alzheimer's, Parkinson's, and Epilepsy. It is currently operational in over 280 sites in India, Africa, and the Middle East and recently received the US FDA 510 clearance for sales in the US market.